ZBH Zimmer Biomet (ZBH) Insider Trading, Ownership & Congress Trades
Medical Devices · Orthopedic, prosthetic & surgical appliances & supplies · CIK 0001136869
Form 144 · 2
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
408
13F, latest reported quarter
Conversions, 180 days
3
Codes C/M, not in net · $0 priced
What the filings say about ZBH
Insiders, 180 days
-$1.2M net sold
3 sellers · 0% of sales under a 10b5-1 plan
Congress, 1 year
No trades
Last one: sale, 2025-05-15
Planned sales (Form 144), 90 days
$824.0K
2 notices
Zimmer Biomet insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, ZIMMER BIOMET HOLDINGS, INC. insiders sold a net $1.2M of stock across 35 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- 1 other insider sold within 30 days.
- 408 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Grp Pres-Global Business Thornal Kevin R sold about $529.0K of ZBH on Sep 11, 2026, the largest insider sale at the company since 2024; 1 other insider sold within 30 days and 408 funds added in the latest 13F quarter.Context
- 9 earlier Form 4 trades (code P or S) here by this insider (9 sales), the last on Feb 22, 2024.
- The trade is 4.6% of the 65,231 shares held after it.
- 1 other insider sold within 30 days.
- 408 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See remarks below. Phipps Chad F sold about $295.1K of ZBH on Sep 4, 2026; 1 other insider sold within 30 days and 408 funds added in the latest 13F quarter.Context
- 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on Feb 12, 2026.
- The trade is 15.0% of the 28,051 shares held after it.
- No other insider sold within 30 days.
- 408 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Group President, Asia Pacific Yi Sang sold about $347.1K of ZBH on May 29, 2026, the largest insider sale at the company since 2024; 408 funds added in the latest 13F quarter.Context
- 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on Feb 12, 2026.
- The trade is 2.9% of the 27,251 shares held after it.
- No other insider sold within 30 days.
- 408 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Group President, Asia Pacific Yi Sang sold about $66.1K of ZBH on May 29, 2026; 408 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Sep 8, 2025.
- The trade is 25.9% of the 10,224 shares held after it.
- 1 other insider sold within 30 days.
- 408 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP and CHRO Winkler Lori sold about $250.8K of ZBH on Mar 12, 2026, the largest insider sale at the company since 2024; 1 other insider sold within 30 days and 408 funds added in the latest 13F quarter.35 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$1.2M over 180 days
-$824.0K over 90 days
below 64% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
408 funds bought in last quarter
more than 92% of Medical Devices
Revenue
+7.2% year over year
below 57% of Medical Devices
Margin
8.6% net margin
more than 80% of Medical Devices
Buybacks
$500.8M repurchased, FY to 2026-06-30
more than 88% of Medical Devices
Short interest
5.1% of the float short (float per yahoo 2026-10-26) · 4.4 days to cover · settled 2026-09-30
more than 63% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch ZBH
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-6.1%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns ZBH: institutional holders (13F)
13F holdings, latest reported quarter
24,124,735 sh
$2.1B
15,614,847 sh
$1.3B
12,738,025 sh
$1.1B
12,634,937 sh
$1.1B
12,183,614 sh
$1.0B
Congress trades in ZBH
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2025-05-15 · disclosed 16 days later
$1,001 - $15,000
Bought 2025-04-08 · disclosed 30 days later
$1,001 - $15,000
Sold 2025-02-11 · disclosed 29 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
ZBH planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Thornal Kevin R
Filed 2026-09-11
$529.0K
Phipps Chad F
Filed 2026-09-04
$295.1K
Upadhyay Suketu
Filed 2026-07-16
$712.1K
Upadhyay Suketu
Filed 2026-06-24
$410.7K
ZBH mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
EIC Value Fund
$11.5M position · as of 2026-07-31
3.0%
Hillman Value Fund
$2.2M position · as of 2026-06-30
2.8%
MFG Global Sustainable Fund
$393.7K position · as of 2026-06-30
2.8%
iShares U.S. Medical Devices ETF
$78.0M position · as of 2026-06-30
2.6%
Oakmark U.S. Large Cap ETF
$26.1M position · as of 2026-06-30
2.5%
First Trust Health Care AlphaDEX Fund
$25.9M position · as of 2026-07-31
2.5%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Corporate PAC
The company's PAC: committee totals only, never individual donors (FEC).
Zimmer Biomet Holdings, Inc. Political Action Committee (A.K.A. 'Zimmer Biomet Pac')
Cycle 2026 · $98K spent
$79.2K
Federal Election Commission, matched by the PAC's connected organisation
Executive pay vs shareholder return · Mr Tornos
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$15.0M
$9.2M
$3.9M
-27%
+17%
2022
$16.4M
$20.5M
$4.7M
-13%
-3%
2021
$15.0M
-$1.1M
$4.2M
-17%
+19%
2020
$13.0M
$7.4M
$3.4M
+4%
+18%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $1.2M sold by insiders over 180 days, 408 funds added last quarter, $824.0K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
ZBH financials
Revenue growth
+7.2%
XBRL, annual
Net margin
8.6%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$8.5B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM ZBH
| FY Dec 2025 | $8.2B |
| FY Dec 2024 | $7.7B |
| FY Dec 2023 | $7.4B |
| FY Dec 2022 | $6.9B |
| FY Dec 2021 | $7.8B |
| Jun 2026 | $2.2B |
| Mar 2026 | $2.1B |
| Dec 2025 | $2.2B |
| Sep 2025 | $2.0B |
| Jun 2025 | $2.1B |
| Mar 2025 | $1.9B |
| Dec 2024 | $2.0B |
| Sep 2024 | $1.8B |
At each fiscal year end
Single quarter
Net margin, TTM
+9.5%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM ZBH
| FY Dec 2025 | +8.6% |
| FY Dec 2024 | +11.8% |
| FY Dec 2023 | +13.8% |
| FY Dec 2022 | +3.3% |
| FY Dec 2021 | +5.1% |
| Jun 2026 | +9.1% |
| Mar 2026 | +11.4% |
| Dec 2025 | +6.2% |
| Sep 2025 | +11.5% |
| Jun 2025 | +7.4% |
| Mar 2025 | +9.5% |
| Dec 2024 | +11.8% |
| Sep 2024 | +13.7% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$1.5B
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM ZBH
| FY Dec 2025 | $1.5B |
| FY Dec 2024 | $1.3B |
| FY Dec 2023 | $1.3B |
| FY Dec 2022 | $1.3B |
| FY Dec 2021 | $1.4B |
| Jun 2026 | $393.6M |
| Mar 2026 | $323.1M |
| Dec 2025 | $442.6M |
| Sep 2025 | $363.7M |
| Jun 2025 | $328.1M |
| Mar 2025 | $338.2M |
| Dec 2024 | $454.8M |
| Sep 2024 | $351.2M |
At each fiscal year end
Single quarter
Debt to equity
0.59x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity ZBH
| FY Dec 2025 | 0.59x |
| FY Dec 2024 | 0.50x |
| FY Dec 2023 | 0.46x |
| FY Dec 2022 | 0.47x |
| FY Dec 2021 | 0.56x |
| Jun 2026 | 0.59x |
| Mar 2026 | 0.59x |
| Dec 2025 | 0.59x |
| Sep 2025 | 0.64x |
| Jun 2025 | 0.60x |
| Mar 2025 | 0.58x |
| Dec 2024 | 0.50x |
| Sep 2024 | 0.52x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.23x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt ZBH
| FY Dec 2025 | 0.23x |
| FY Dec 2024 | 0.24x |
| FY Dec 2023 | 0.27x |
| FY Dec 2022 | 0.26x |
| FY Dec 2021 | 0.21x |
| Jun 2026 | 0.23x |
| Mar 2026 | 0.22x |
| Dec 2025 | 0.23x |
| Sep 2025 | 0.21x |
| Jun 2025 | 0.22x |
| Mar 2025 | 0.23x |
| Dec 2024 | 0.24x |
| Sep 2024 | 0.25x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+6.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity ZBH
| FY Dec 2025 | +5.6% |
| FY Dec 2024 | +7.2% |
| FY Dec 2023 | +8.4% |
| FY Dec 2022 | +1.9% |
| FY Dec 2021 | +3.2% |
| Jun 2026 | +6.4% |
| Mar 2026 | +6.1% |
| Dec 2025 | +5.6% |
| Sep 2025 | +6.4% |
| Jun 2025 | +6.5% |
| Mar 2025 | +7.3% |
| Dec 2024 | +7.2% |
| Sep 2024 | +8.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+3.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets ZBH
| FY Dec 2025 | +3.2% |
| FY Dec 2024 | +4.2% |
| FY Dec 2023 | +4.8% |
| FY Dec 2022 | +1.0% |
| FY Dec 2021 | +1.7% |
| Jun 2026 | +3.5% |
| Mar 2026 | +3.4% |
| Dec 2025 | +3.2% |
| Sep 2025 | +3.6% |
| Jun 2025 | +3.7% |
| Mar 2025 | +4.2% |
| Dec 2024 | +4.2% |
| Sep 2024 | +5.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+5.3%
operating income after a 13.6% effective tax rate, over long-term 2026-06-30 plus current 2026-06-30 plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital ZBH
| FY Dec 2025 | +4.8% |
| FY Dec 2024 | +6.2% |
| FY Dec 2023 | +7.0% |
| FY Dec 2022 | +2.8% |
| FY Dec 2021 | +4.1% |
| Jun 2026 | +5.3% |
| Mar 2026 | +5.2% |
| Dec 2025 | +4.8% |
| Sep 2025 | +5.3% |
| Jun 2025 | +5.4% |
| Mar 2025 | +6.1% |
| Dec 2024 | +6.2% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+6.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed ZBH
| FY Dec 2025 | +5.6% |
| FY Dec 2024 | +6.8% |
| FY Dec 2023 | +6.8% |
| FY Dec 2022 | +3.6% |
| FY Dec 2021 | +4.1% |
| Jun 2026 | +6.0% |
| Mar 2026 | +5.9% |
| Dec 2025 | +5.6% |
| Sep 2025 | +6.8% |
| Jun 2025 | +6.6% |
| Mar 2025 | +6.8% |
| Dec 2024 | +6.8% |
| Sep 2024 | +6.7% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
23.32x
close 2026-10-27 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing ZBH
| FY Dec 2025 | 25.33x |
| FY Dec 2024 | 23.79x |
| FY Dec 2023 | 24.94x |
| FY Dec 2022 | 115.91x |
| FY Dec 2021 | 64.92x |
| Jun 2026 | 20.90x |
| Mar 2026 | 23.42x |
| Dec 2025 | 25.33x |
| Sep 2025 | 24.44x |
| Jun 2025 | 22.25x |
| Mar 2025 | 25.10x |
| Dec 2024 | 23.79x |
| Sep 2024 | 20.56x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$25.4B
market value at close 2026-10-27 on 2026-07-30 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value ZBH
| FY Dec 2025 | $24.7B |
| FY Dec 2024 | $26.7B |
| FY Dec 2023 | $30.8B |
| FY Dec 2022 | $32.1B |
| FY Dec 2021 | $32.5B |
| Jun 2026 | $23.7B |
| Mar 2026 | $24.7B |
| Dec 2025 | $24.7B |
| Sep 2025 | $26.3B |
| Jun 2025 | $25.1B |
| Mar 2025 | $28.3B |
| Dec 2024 | $26.7B |
| Sep 2024 | $27.9B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+8.3%
TTM free cash flow over market value at close 2026-10-27
FCF yield ZBH
| FY Dec 2025 | +8.3% |
| FY Dec 2024 | +6.2% |
| FY Dec 2023 | +5.1% |
| FY Dec 2022 | +4.9% |
| FY Dec 2021 | +5.3% |
| Jun 2026 | +9.1% |
| Mar 2026 | +8.2% |
| Dec 2025 | +8.3% |
| Sep 2025 | +7.6% |
| Jun 2025 | +8.2% |
| Mar 2025 | +6.5% |
| Dec 2024 | +6.2% |
| Sep 2024 | +6.2% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
47.80x
P/E over trailing EPS growth of 0%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing ZBH
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | 0.07x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 42.84x |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | 0.16x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $8.2B | $7.7B | $7.4B | $6.9B |
| Operating income | $1.1B | $1.3B | $1.3B | $696.3M |
| Net income | $705.1M | $903.8M | $1.0B | $231.4M |
| EPS (diluted) | 3.55 | 4.43 | 4.88 | 1.10 |
| Operating cash flow | $1.7B | $1.5B | $1.6B | n/a |
| Cash | $591.9M | $525.5M | $415.8M | $375.7M |
| Long-term debt | $6.9B | $5.3B | $4.9B | $5.2B |
| Buybacks | $487.0M | $868.0M | $692.2M | $126.4M |
| Dividends paid | $190.3M | $196.0M | $200.9M | $201.2M |
SEC XBRL, fiscal years, as known on 2026-10-28
ZBH Stock Sonar score 6/7 axes
Find similar shapesCompareZBH ranks highest on institutional and government (92nd percentile) and profitability (62nd), and lowest on insider conviction (17th), among Medical Devices peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
ZBH filings, in plain words
Are Zimmer Biomet insiders buying or selling ZBH?
In the 180 days to 2026-10-28, Zimmer Biomet insiders were net sellers, a net $1.2M across purchases and sales reported on Form 4, by 3 sellers.
Have members of Congress traded ZBH?
Yes, but not in the year to 2026-10-28; the latest on record is a sale by Rob Bresnahan dated 2025-05-15.
Are there planned insider sales of ZBH?
Yes. 2 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $824.0K of stock; the latest, by Thornal Kevin R, was filed 2026-09-11.
Read the full summary
In the 180 days to 2026-10-28, Zimmer Biomet insiders were net sellers of ZBH, a net $1.2M across purchases and sales reported on Form 4 by 3 sellers. None of the 4 insider sales was flagged as made under a Rule 10b5-1 plan. Members of Congress have disclosed trades in ZBH, none in the last year; the latest on record is a sale by Rob Bresnahan dated 2025-05-15. Insiders filed 2 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $824.0K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
